Axonics, Inc CEO Raymond Cohen

Raymond W. Cohen is an accredited public company director and currently serves as the CEO and member of the board of directors of Axonics, Inc., (Nasdaq: AXNX) a medical device company focused on the treatment of bladder and bowel disorders. In January 2024, Axonics agreed to be acquired by Boston Scientific Corp for $3.7 billion. In January 2024, Cohen was named the Businessperson of the Year in Orange County, CA’s health industry by the OC Business Journal.

In 2023, in only its fourth year of commercial activity in the US, Axonics generated $366 million in revenue at a 75% gross margin and generated nearly $50 million in positive adjusted EBITDA. November 2021, Axonics was ranked on Deloitte’s Technology Fast 500 listing at the #1 fastest growing company in North America based on growth of 87,000+ percent from 2017 to 2020. In December 2021, Mr. Cohen received a lifetime achievement award from SoCal Bio for his four decades of work in medical technology. In October 2020, Cohen was named as Entrepreneur of the Year by Ernst & Young for the Southwest US. Cohen also currently serves as Chairman of BiVACOR, Inc., a privately held Orange County based MedTech company developing a total artificial heart. He also serves as an independent director for SoniVie, Ltd., a privately held Israeli based MedTech company developing a device treated for hypertension as well as Euclid Vision, a PE backed MedTech company marketing products for vision care with over half of its revenue coming from China. For 15 years until mid-2021, Cohen served as Chairman of BioLife Solutions Inc. (Nasdaq: BLFS). Previously, Cohen served on the boards of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI), Zurich-based LifeWatch (LIFE.SW) which was acquired by BioTelemetry (Nasdaq: BEAT) and privately held Syncroness, Inc. sold to ALTEN Group, a French multi-billion-dollar engineering services company.

From 2010 to 2012, Mr. Cohen served as the CEO of Vessix Vascular, Inc., a device developer which was acquired by Boston Scientific Corp. in late 2012. Prior, Cohen was CEO of Nasdaq-listed, Cardiac Science, Inc., ranked by Deloitte as the 4th fastest growing company in North America in 2004. In his career, Mr. Cohen has been directly responsible for raising approx. $2 billion in capital. Mr. Cohen holds a B.S. in Business Management from Binghamton University in NY.